Provided by Tiger Fintech (Singapore) Pte. Ltd.

LUYE PHARMA

3.500
-0.020-0.57%
Volume:59.45M
Turnover:207.53M
Market Cap:13.17B
PE:25.49
High:3.580
Open:3.510
Low:3.430
Close:3.520
Loading ...

Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S

Reuters
·
17 Jun

Luye Pharma Group Ltd. Conducted Annual General Meeting

Reuters
·
28 May

Hong Kong Stocks Reverse Early Losses to End Higher; Pharma Stocks Slide

MT Newswires Live
·
09 Apr

Hong Kong Pharma Stocks Decline as Trump Threatens Tariffs on Imported Drugs

MT Newswires Live
·
09 Apr

Luye Pharma Gets Macao Approval for Antidepressant

MT Newswires Live
·
08 Apr

BRIEF-Luye Pharma Says Antidepressant Ruoxinlin Approved For Marketing In Macao

Reuters
·
07 Apr

Luye Pharma - Class 1 Innovative Antidepressant Ruoxinlin Approved for Marketing in Macao

THOMSON REUTERS
·
07 Apr

Luye Pharma Group Rivastigmine Patch Approved for Alzheimer's Treatment in Japan

MT Newswires Live
·
01 Apr

Luye Pharma - Rivastigmine Twice Weekly Transdermal Patch- Approved for Marketing in Japan

THOMSON REUTERS
·
31 Mar

Institutions profited after Luye Pharma Group Ltd.'s (HKG:2186) market cap rose HK$451m last week but private companies profited the most

Simply Wall St.
·
20 Mar

Investors Appear Satisfied With Luye Pharma Group Ltd.'s (HKG:2186) Prospects

Simply Wall St.
·
11 Feb

Luye Pharma Group Enrolls First Patient in Phase II Trial for New Huntington's Disease Drug

MT Newswires Live
·
16 Jan

Luye Pharma Gets US FDA Approval for Clinical Trials for Schizophrenia Drug

MT Newswires Live
·
15 Jan

BRIEF-Luye Pharma Says Approval Obtained For Group's New Drug Ly03020 For Clinical Trials In U.S.

Reuters
·
14 Jan

Luye Pharma - Approval Obtained for Group's New Drug Ly03020 for Clinical Trials in U.S.

THOMSON REUTERS
·
14 Jan